395results about "Organic active ingredients" patented technology

The invention relates to small sized particles. These particles comprise at least on the surface thereof a wall composed of a mixture of at least one protein and at least one polysaccharide which are cross-linked, preferably by interfacial cross-linking with a polyfunctional acylating agent which forms at least amide and ester bonds, and optionally anhydride bonds with amine, hydroxyl or carboxyl functions of the protein and of the polysaccharide, and which comprise hydroxamic groups on the surface thereof for chelating metal ions. These particles can be used in cosmetics or in pharmacy notably for the chelation or release of metal ions.

The present invention provides a monoclonal anti-idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological response to HMFG in nice, rabbits, monkeys and patients with advanced HMFG-associated tumors. This invention provides compositions derived from polynucleotide sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 11D10, as well as polypeptides encoded thereby. The invention also provides compositions which can be used in the detection or treatment of HMFG-associated tumors.

A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.

Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.

The invention provides a CRISPR-Cas9 system for preventing and/or treating HIV, as well as a preparation method and application thereof. The CRISPR-Cas9 system comprises sgRNA of a specific genetic locus on a specific target HIV genome, wherein the specific genetic locus on the HIV genome is selected from Gag, Env, Pol, Tat, Nef, Vif, Vpr, Vpu, 5'LTR, 3'LTR and Rev. The preparation method of the CRISPR-Cas9 system comprises the step of preparing an sgRNA fragment by means of PCR amplification. The invention further provides application of the CRISPR-Cas9 system in preparation of medicines for treating and/or preventing HIV infection. By adopting an efficient gene delivery system, the CRISPR-Cas9 system is delivered into HIV infected cells to efficiently inhibit generation of HIV, the inhibition rate is 96 percent, and the effect equivalent to that of peptide anti-HIV medicines can be achieved.

The present invention provides substituted 2-aminopyridines of formula I, wherein R1, A1, W, X, and Y are as defined in the specification, useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (Cdk4).

Pharmaceutical composition comprising micro particles having an average diameter ranging from 40 to 150 nm, consisting of one or more lipids, a drug and, optionally, a steric stabilizer, suitable to the transmucosal passage and to the overcoming of the blood-brain barrier and the blood-cerebrospinal fluid barrier, said micro particles being obtained dispersing in an aqueous medium cooled to 2-4° C. an oil/water or a water/oil/water micro emulsion comprising said constituents.

Hydrotropic polymer micelles effective for increasing the water solubility of poorly soluble drugs are described. Such hydrotropic polymer micelles have the combined properties of polymer micelles and hydrotropic agents, which display a synergistic effect for increasing the solubility of such drugs. Hydrotropic polymer micelles are formed in solution from amphiphilic copolymers that comprise a hydrophilic polymer and a hydrophobic polymer having pendant hydrotropic agents. A preferred copolymer is a di-, tri- or multi-block copolymer composed of hydrophilic and hydrophobic polymer chains. A particularly preferred hydrophilic chain comprises polyethyleneoxide (PEG) and a preferred hydrophobic chain comprises hydrotropic monomer units derived from nicotinamide. The micelles are found to be much more effective in solubilizing poorly soluble drugs and exhibit an excellent long-term stability even at high loading of drugs. A hydrotropic polymer micelle has nanometer scale size, by which they can deliver poorly soluble drugs to the body through diverse routes of administration.

Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compositions comprising the prepared particles as well as methods of use are also provided.

The invention discloses 2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl) acetic acid(I) and an optical isomer(II) thereof; and the invention also discloses a method for preparing the compound and the application of the compound in the preparation of ramelteon which is a medicament for treating insomnia.

A pyrrolo[3,2-d]pyrimidine compound, such as a compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

Methods and compositions for diagnosing and treating glaucoma are disclosed.

The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.

The present invention concerns the preparation of composite biomaterials constituted by hyaluronic acid and the derivatives thereof in combination with polymers that have electrically conductive properties. In particular, the methods of preparing biomedical devices formed by a two- or three-dimensional polysaccharide matrix and by an electrically conductive membrane. The matrix is constituted by hyaluronic acid derivatives in the form of membranes, woven fabrics, nonwoven felts, meshes, gauzes, guide channels or sponges, while the electrically conductive membrane is constituted by a film of polypyrrole (polymer conductor) in combination with hyaluronic acid or a derivative thereof (doping agent).

The present invention is directed to a hard capsule filled with a solution containing an active ingredient, characterized in that the solution contains an inorganic chloride and has a water content (w) of 10<w≦80% and a water activity (a) of 0.50≦a≦0.90, and that the capsule is made of a base material containing a cellulose derivative. According to the present invention, a solution having high water content can be encapsulated, with its solution form being maintained. Thus, the present invention enables provision of a product which does not impair properties and stability of a drug or a similar substance, and does not impair sensation upon intake or eating sensation.

We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.

The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.

Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.

The present invention discloses one kind of aryl formyl piperazine compound and its preparation process and application in preparing medicine. The compound and its medicinal salt have the general expressions shown. The compound may be used in preparing medicine for arrhythmia. The compound has rich material source, mild reaction condition and simple preparation process and post-treatment.

A freeze-dried nano-suspension of nimodipine for intravenous injection with low stimulation and high curative effect and stability contains nimodipine, surfactant and scaffolding agent. Its preparing process and application are also disclosed.

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula.

The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4′-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.